The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Treatment options for myeloma patients who relapse after BCMA-directed therapies
Juan Du, MD, Changzheng Hospital, The Second Military Medical University, Shanghai, China, discusses treatment options for myeloma patients who relapse or are refractory to BCMA-directed therapies. Dr Du explains that while carfilzomib-based regimens and anti-CD38 antibodies are promising, more head-to-head comparison trials are required to improve options for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
